Avidity Partners Management’s Nuvation Bio NUVB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-4,855,000
Closed -$15.7M 103
2022
Q2
$15.7M Sell
4,855,000
-6
-0% -$26 0.36% 44
2022
Q1
$25.5M Sell
4,855,006
-2,527,482
-34% -$14.2M 0.53% 48
2021
Q4
$62.8M Buy
7,382,488
+119,000
+2% +$1.09M 1.33% 25
2021
Q3
$72.2M Buy
7,263,488
+297,112
+4% +$2.69M 1.6% 19
2021
Q2
$64.9M Sell
6,966,376
-555,565
-7% -$6.34M 1.75% 17
2021
Q1
$78.6M Buy
+7,521,941
New +$84.1M 2.17% 14

Other funds holding NUVB

Avidity Partners Management's NUVB Position: Q3 2022 in Review

Avidity Partners Management sold out of Nuvation Bio (NUVB) in Q3 2022, closing a stake of 4,855,000 shares — an estimated $15.7M sold.

Avidity Partners Management first reported a position in NUVB in Q1 2021 and held it in 6 quarters. The position peaked at $78.6M in Q1 2021. 121 funds tracked by Wall St. Rank hold NUVB as of Q3 2022.

  • Avidity Partners Management reported no remaining Nuvation Bio position as of Q3 2022 after selling out during the quarter.
  • Avidity Partners Management sold 4,855,000 Nuvation Bio shares in Q3 2022, an estimated $15.7M.
  • Avidity Partners Management first reported a position in Nuvation Bio in Q1 2021 and held it in 6 quarters.
  • Avidity Partners Management's Nuvation Bio position peaked at $78.6M in Q1 2021.
  • 121 funds tracked by Wall St. Rank held Nuvation Bio as of Q3 2022.

Based on Avidity Partners Management's 13F filing for Q3 2022, filed 14 Nov 2022.